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Impaired Notch Signaling Promotes De novo Squamous Cell Carcinoma
Formation
Abstract
Signaling through Notch receptors in the skin has been implicated in the differentiation, proliferation, and
survival of keratinocytes, as well as in the pathogenesis of basal cell carcinoma (BCC). To determine the
composite function of Notch receptor–mediated signaling in the skin and overcome potential redundancies
between receptors, conditional transgenic mice were generated that express the pan-Notch inhibitor,
dominant-negative Mastermind Like 1 (DNMAML1), to repress all canonical [CBF-1/Suppressor of
hairless/LAG-1 (CSL)–dependent] Notch signaling exclusively in the epidermis. Here, we report that
DNMAML1 mice display hyperplastic epidermis and spontaneously develop cutaneous squamous cell
carcinoma (SCC) as well as dysplastic precursor lesions, actinic keratoses. Mice expressing epidermal
DNMAML1 display enhanced accumulation of nuclear ß-catenin and cyclin D1 in suprabasilar keratinocytes
and in lesional cells from SCCs, which was also observed in human cutaneous SCC. These results suggest a
model wherein CSL-dependent Notch signaling confers protection against cutaneous SCC. The
demonstration that inhibition of canonical Notch signaling in mice leads to spontaneous formation of SCC
and recapitulates the disease in humans yields fundamental insights into the pathogenesis of SCC and
provides a unique in vivo animal model to examine the pathobiology of cutaneous SCC and for evaluating
novel therapies.
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Abstract
Signaling through Notch receptors in the skin has been
implicated in the differentiation, proliferation, and survival of
keratinocytes, as well as in the pathogenesis of basal cell
carcinoma (BCC). To determine the composite function of
Notch receptor–mediated signaling in the skin and overcome
potential redundancies between receptors, conditional trans-
genic mice were generated that express the pan-Notch inhib-
itor, dominant-negative Mastermind Like 1 (DNMAML1), to
repress all canonical [CBF-1/Suppressor of hairless/LAG-1
(CSL)–dependent] Notch signaling exclusively in the epider-
mis. Here, we report that DNMAML1 mice display hyperplastic
epidermis and spontaneously develop cutaneous squamous
cell carcinoma (SCC) as well as dysplastic precursor lesions,
actinic keratoses. Mice expressing epidermal DNMAML1
display enhanced accumulation of nuclear B-catenin and
cyclin D1 in suprabasilar keratinocytes and in lesional cells
from SCCs, which was also observed in human cutaneous SCC.
These results suggest a model wherein CSL-dependent Notch
signaling confers protection against cutaneous SCC. The
demonstration that inhibition of canonical Notch signaling
in mice leads to spontaneous formation of SCC and
recapitulates the disease in humans yields fundamental
insights into the pathogenesis of SCC and provides a unique
in vivo animal model to examine the pathobiology of
cutaneous SCC and for evaluating novel therapies. (Cancer
Res 2006; 66(15): 7438-44)
Introduction
Notch signaling regulates multiple cellular processes, including
differentiation, proliferation, and cell fate decisions, required for
organogenesis and tissue homeostasis ( for review, see refs. 1, 2).
Notch receptor–mediated signaling is cell type dependent and
developmentally regulated, underscoring the importance of other
molecular pathways that modulate activity of this signaling
pathway (3, 4). In mammals, there are four transmembrane Notch
receptors (Notch1-Notch4) that are activated via binding ligands of
the Delta and Jagged families. In the canonical Notch signaling
pathway, Notch receptor stimulation results in cleavage of the
Notch intracellular domain, which translocates to the nucleus and
forms a ternary complex with the transcriptional coactivator,
mastermind-like (MAML) protein, as well as the DNA-binding
protein, CSL, which directs DNA-binding specificity and ultimately
target gene expression (5). To date, only a limited number of Notch
target genes have been identified and characterized, including
basic-helix-loop-helix proteins of the hairy and enhancer of split
(Hes) and Hes-related transcription factor (Hrt) families, which
generally act as transcriptional repressors (6).
Notch receptors are expressed in the skin, although their precise
function(s) remain uncertain ( for review, see ref. 7). In keratino-
cytes, activated Notch1 induces p21 expression in a CSL-dependent
manner, leading to cell cycle withdrawal and terminal differenti-
ation (8). In addition, Notch1 directly activates caspase 3, which is
required for terminal differentiation of embryonic keratinocytes
(9). Consistent with its role in promoting differentiation of
keratinocytes, mice with an induced epidermal deletion of the
Notch1 gene exhibit extensive epidermal hyperplasia and sponta-
neously develop cutaneous basal cell carcinoma (BCC; ref. 10).
This finding led investigators to propose that, in the skin, Notch1
acts as a tumor suppressor (10, 11). Moreover, in mice with condi-
tional epidermal inactivation of Notch1, chemical injury induced
the formation of cutaneous lesions resembling both BCC and
squamous cell carcinoma (SCC), in addition to inducing numerous
papillomas (10).
Neoplasms originating from cutaneous epithelial cells, including
BCC and SCC, are the most common cancers in the United States
with annual incidences of nearly 1 million and 250,000 cases,
respectively (reviewed in refs. 12–14). Unlike BCC, SCCs are bio-
logically aggressive, arise from precursor lesions (actinic keratoses),
and display metastatic potential with frequencies approaching
12.5%. Mutations in components of the sonic hedgehog (SHH)
signaling pathway have been implicated in the etiology of both
human and mouse BCC (15–18). By contrast, genetic mutations
uniquely causing human SCC have not been identified (17). Under-
standing the role of Notch signaling in BCC and chemically induced
SCC is fundamentally important, given the dramatic differences
in the pathobiology and clinical manifestations of these common
cutaneous malignancies.
To better understand the role of Notch1-4 receptor signaling
in the skin, we generated mice expressing a dominant negative
MAML1 (DNMAML1) protein to inhibit CSL-dependent Notch
signaling in the epidermis. DNMAML1 mice exhibited multiple
skin defects including diffuse alopecia, epidermal hyperplasia,
and hyperkeratinization. Surprisingly, these mice developed spon-
taneous lesions resembling human SCC and actinic keratoses, but
did not develop BCC. In contrast to normal epidermis, keratino-
cytes and lesional cells from DNMAML1 mutant mice expressed
nuclear h-catenin and cyclin D1 in a pattern similar to that
observed in human cutaneous SCC, suggesting a conserved role
for these molecules in SCC. Taken together, these data strongly
suggest that functional interactions between Notch signaling and
h-catenin and cyclin D1 play critical roles in the pathogenesis of
cutaneous SCC.
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Materials and Methods
Generation and characterization of SM22-Cre+/DNMAML1+
conditional transgenic mice. SM22-Cre transgenic mice, expressing Cre
recombinase under the transcriptional control of the 2.8-kb mouse SM22a
promoter, have previously been described (19). DNMAML1f/f mice,
heretofore designated as DNMAML1+ conditional transgenic mice, express-
ing the DNMAML1-enhanced green fluorescent protein (EGFP) fusion
protein, were previously described (20). DNMAML1+ mice in the FVBN
background were intercrossed with SM22-Cre transgenic mice in the CD1
background, generating mice expressing DNMAML1 under the transcrip-
tional control of the SM22a promoter, designated SM22-Cre+/DNMAML1+,
and control littermates lacking Cre recombinase, designated SM22-Cre/
DNMAML1+, in a mixed FVBN/CD1 genetic background. For the cell fate
mapping studies, SM22-Cre transgenic mice were intercrossed to the R26R
indicator strain (21) and h-galactosidase activity was assessed in the
informative offspring as previously described (19). To assess the endogenous
pattern of SM22a gene expression during mouse embryonic development,
SM22a-LacZ mice, in which the LacZ gene was knocked into the
endogenous SM22a allele (22), were harvested during embryonic develop-
ment and stained for h-galactosidase activity as previously reported (19).
All mouse experimentation was done under approved protocols from the
University of Pennsylvania Animal Care and Use Committee and NIH
guidelines.
Human tissue. Formalin-fixed, paraffin-embedded tissue samples of
invasive SCC from skin were collected from the dermatopathology archives
of the University of Pennsylvania Department of Dermatology with Internal
Review Board approval under protocol 704450.
Immunohistochemistry and 5-bromo-4-chloro-3-indolyl-B-D-
galactopyranoside staining. Mouse skin and tumor specimens fixed in
2% paraformaldehyde were subjected to either standard H&E staining or
immunohistochemical staining with Texas red–conjugated secondary
antibody and Hoechst counterstain. Primary antibodies used in the study
include anti-GFP (1:100, Molecular Probes, Eugene, OR), anti-h-catenin
(1:100, Sigma, St. Louis, MO), and anti–cyclin D1 (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA). 5-Bromo-4-chloro-3-indolyl-h-D-galactopyr-
anoside (X-gal) staining of embryonic and adult tissue was done as
described (19) with light eosin counterstain. Histology protocols may be
assessed on the University of Pennsylvania Molecular Cardiology website at
http://www.uphs.upenn.edu/mcrc/histology/histologyhome.html.
Results
Generation of conditional transgenic mice with epidermal-
restricted inhibition of Notch signaling. To determine the
function of CSL-dependent Notch signaling in skin, SM22-Cre
transgenic mice were intercrossed with genetically engineered
DNMAML1+ mice, in which the cDNA encoding DNMAML1 fused
to GFP was knocked into the ROSA locus (20, 23). Our group and
others have reported that during postnatal development, SM22a
promoter activity is restricted to vascular and visceral smooth
muscle cells, including the smooth muscle–containing arrector
pili muscle within adult skin (Fig. 1A, arrows ; refs. 24, 25).
Surprisingly, we also observed transient activity of the SM22a
promoter in the epidermis of the embryonic mouse at midgesta-
tion. At embryonic day (E)12.5, in SM22a-LacZ embryos, in which
the LacZ gene was ‘‘knocked in’’ to the endogenous SM22a allele
(22), h-galactosidase activity (blue stain) is clearly shown in the
epidermis (Fig. 1C and E) but staining was not observed in con-
trol littermates (Fig. 1B and D). Consistent with these find-
ings, intercrossing SM22-Cre transgenic mice with R26R-LacZ
indicator mice, which provides a fate map of cells in which the
SM22a promoter was ever active, showed intense blue staining
indicative of h-galactosidase activity in the epidermis of adult
SM22-Cre+/R26R-LacZ+ progeny (Fig. 1G), which was not observed
in littermate controls (Fig. 1F). Importantly, long-term LacZ
expression was observed in both interfollicular (basal and supra-
basal layers) and follicular (outer and inner root sheath) epithelium
(Fig. 1G, arrows). Because stem cells within the basal epidermis
and the bulge region associated with the hair follicle outer root
sheath (Fig. 1F and G, brackets) are required for normal keratino-
cyte renewal and hair follicle cycling (26), these data show that
prenatal Cre activation must occur in at least a subset of the
proliferating epithelial cells destined to contribute to the adult
epidermal stem cell population.
Characterization of SM22-Cre+/DNMAML1+ mutant mice.
When SM22-Cre transgenic mice were intercrossed with DNMAML1
conditional transgenic mice, viable SM22-Cre+/DNMAML1+ proge-
ny were born in the anticipated Mendelian ratio. Beginning 2 to
3 weeks after birth, these mice exhibited diffuse loss of body
hair and whiskers, and with further aging, hyperkeratinization
of the tail was observed [Fig. 2A (top) and data not shown]. Alo-
pecia progressed to near completion by 10 months of age (data
not shown). Generalized growth retardation was also noted in
Figure 1. SM22a promoter activity in embryonic skin directs Cre recombinase
expression in keratinocytes required for normal adult skin homeostasis.
A, X-gal staining of backskin from an adult SM22a+/LacZmouse (arrows,
arrector pili). B to E, X-gal staining of cranial sections from day (E)12.5 SM22a+/+
(B ) and SM22a+/LacZ (C ) littermate embryos. Arrowheads, surface epithelium.
V4, V3, and L, fourth, third, and lateral ventricular spaces, respectively.
C, arrow, basilar artery. Boxed regions in (B and C ) are shown enlarged in
(D and E ), respectively, with brackets encompassing the surface epithelium.
F and G, X-gal staining of backskin from control SM22-Cre  R26R (F ) and
SM22-Cre+  R26R (G) mice in telogen phase. Staining of the interfollicular
and follicular epidermis (arrows ) and the bulge region (bracket ) is shown.
Arrowheads, arrector pili.
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SM22-Cre+/DNMAML1+ mice. By contrast, SM22-Cre/DNMAML1+
control littermates exhibited normal body hair and size (Fig. 2A,
bottom). Immunohistochemical staining for GFP, indicative of
expression of the DNMAML1-GFP fusion protein, showed GFP
expression (red color) in the follicular and interfollicular epidermis
in SM22-Cre+/DNMAML1+ mice (Fig. 2E-G) but not in corre-
sponding SM22-Cre/DNMAML1+ skin (Fig. 2B-D). Of note, the
keratinized surface of the skin generates a nonspecific fluorescent
signal in both the control and mutant mice. These observations,
together with the Cre recombinase fate mapping data described
above (Fig. 1G), confirmed that SM22a promoter–directed Cre
recombinase expression results in epidermally restricted expression
of DNMAML1 that begins during midgestation and persists
throughout postnatal development.
To examine cellular alterations in the skin of SM22-Cre+/
DNMAML1+ mice, the backskin of mutant and control mice was
biopsied and subjected to histologic analyses. Multiple aberrant
features were observed in the skin of SM22-Cre+/DNMAML1+ mice
including (i) hypoplastic dermis with increased cellularity, (ii)
epidermal hyperplasia, (iii) keratin cyst formation, and (iv)
aberrant hair follicle cycling (Fig. 3C and D). By contrast, none of
these abnormalities was observed in the skin of SM22-Cre/
DNMAML1+ control littermates (Fig. 3A and B). Similar histologic
findings have been reported in other mouse models of skin-
deficient Notch signaling (10, 27–29), further substantiating the
conclusion that DNMAML1 represses Notch signaling in skin.
SM22-Cre+/DNMAML1+ mutant mice develop de novo SCC.
As early as 6 months of age, most SM22-Cre+/DNMAML1+ mutant
mice began to develop hyperkeratotic cutaneous nodules, with
all SM22-Cre+/DNMAML1+ mice exhibiting multiple lesions by
10 months of age. Figure 4A shows a representative 8-month-old
SM22-Cre+/DNMAML1+ mouse exhibiting exophytic hyperkeratotic
lesions along the dorsal midline [Fig. 4A (lesion I) and B], near the
proximal right upper limb [Fig. 4A (lesion II) and F] and near the
left foot [Fig. 4A (lesion III) and J]. Histologic examination of these
keratinized masses revealed hyperproliferative keratinocytic lesions
exhibiting cellular atypia and an invasive growth pattern diagnostic
of SCC (Fig. 4C-E and G-I). In addition, microscopic examination
of the foot lesion revealed intraepidermal keratinocyte dysplasia
and parakeratosis, consistent with a precursor lesion resembling an
actinic keratosis (Fig. 4J and K). To date, SCC lesions have been
observed in 14 of 16 SM22-Cre+/DNMAML1+ mice with an average
of two SCC lesions per mouse. Histologic analyses of additional,
although infrequent, cutaneous masses in these mice revealed
papillomas, inflamed infundibular cysts, and one cystic teratoma
Figure 3. Adult SM22-Cre+/DNMAML1+ mice display both epidermal and
follicular skin defects. H&E staining of backskin from SM22-Cre/DNMAML1+
[A, low power (10); B, high power (40)] and SM22-Cre+/DNMAML1+ [C, low
power (10); D, high power (40)] mice at telogen growth phase. Brackets,
relative thickness of the dermis (A and C ) and epidermis (B and D ).
Arrowheads, aberrant subdermal follicles; arrows, increased dermal cellularity.
Asterisks, keratin cysts.
Figure 2. SM22-Cre+/DNMAML1+ mice display diffuse
alopecia with epidermal expression of DNMAML1-GFP.
A, representative 8-week-old SM22-Cre+/DNMAML1+
mouse (top ) and SM22-Cre/DNMAML1+ littermate
(bottom ). The SM22-Cre+/DNMAML1+ mouse exhibits
smaller body size in addition to patchy hair loss. B to G,
immunohistochemical analysis of GFP-linked DNMAML1
expression (red ) in longitudinal sections of backskin
from SM22-Cre/DNMAML1+ (B-D ) and SM22-Cre+/
DNMAML1+ (E-G ) mice. Blue, Hoechst nuclear
counterstain. Arrowheads, interfollicular and follicular
basal cells; arrows, suprabasilar keratinocytes. Drawn
white contour lines delineate the cornified layer, which
produces a background fluorescent signal artifact.
Cancer Research
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(data not shown). Remarkably, no BCCs were observed in the
SM22-Cre+/DNMAML1+ mice.
Nuclear B-catenin accumulates in the epidermis of SM22-
Cre+/DNMAML1+ mice and in human SCC. The development of
cutaneous SCC in the SM22-Cre+/DNMAML1+ mice raised the
mechanistic question of what alterations in downstream signaling
pathways occurred in response to pan-Notch inhibition in the
epidermis. Disruptions in Wnt/h-catenin signaling have been
implicated in the pathogenesis of cutaneous SCC (30–32). In
addition, mice harboring an epidermal-restricted null mutation
of Notch1 exhibited accumulation of nuclear h-catenin in their
epidermis and spontaneously arising BCC (10). Therefore, to
examine whether h-catenin signaling was altered in SM22-Cre+/
DNMAML1+ mice, the cellular localization of h-catenin, a surrogate
marker for h-catenin activation, was determined in the skin and
tumor sections from SM22-Cre+/DNMAML1+ mice and littermate
controls. The expected membrane-bound h-catenin (red signal),
representing signaling inactive h-catenin, was observed in folli-
cular and interfollicular epidermal cells in the skin of both control
(Fig. 5A-C, arrow) and mutant mice (Fig. 5D-F, arrow). Membrane-
bound h-catenin was also observed in SCC lesional cells of
SM22-Cre+/DNMAML1+ mice (Fig. 6A, arrow). However, nuclear
h-catenin (red signal), representing activated h-catenin, was ob-
served only in the skin of SM22-Cre+/DNMAML1+ mutant mice
(Fig. 5D and F, arrowheads) but not in the skin of control
littermates (Fig. 5A-C). This was most pronounced in suprabasilar
epidermal keratinocytes. Remarkably, accumulation of nuclear
h-catenin in SCCs of SM22-Cre+/DNMAML1+ mice (Fig. 6A, arrow-
heads) was also seen in biopsies of human cutaneous SCC (Fig. 6B,
arrowheads). Taken together, these results suggest that h-catenin
signaling is activated in de novo SCC arising in SM22-Cre+/
DNMAML1+ mice, recapitulating observations made in human
cutaneous SCC.
Cyclin D1 is up-regulated in the skin of SM22-Cre+/
DNMAML1+ mice. Cyclin D1 is up-regulated by h-catenin
signaling and has been shown to regulate entry into the cell cycle
(33, 34). Given the increased h-catenin activation in cutaneous
SCCs from both SM22-Cre+/DNMAML1+ mice and human tumors,
we examined cyclin D1 gene expression in the skin of SM22-Cre+/
DNMAML1+ mice and human biopsy samples of cutaneous SCC.
In control mice, in which the epidermis typically lacks multiple
suprabasilar layers, expression of cyclin D1 protein (red staining)
was observed in the nucleus of basal epithelial cells, consistent
with the proliferative properties of this undifferentiated cell layer
(Fig. 5G-I, arrowhead). In the skin of SM22-Cre+/DNMAML1+ mice,
nuclear basal cell expression of cyclin D1 was also observed. How-
ever, in the skin of mutant mice, cyclin D1 was enriched in the nuclei
of suprabasilar epidermal cells (Fig. 5J-L, arrowheads). This observa-
tion is consistent with a model in which suprabasilar keratino-
cytes that normally differentiate fail to exit the cell cycle and continue
to proliferate, thereby constituting an aberrant cell population.
Given these findings, we next examined whether cyclin D1
expression was altered in SCC lesions that arose spontaneously in
the SM22-Cre+/DNMAML1+ mice. As shown in Fig. 6C , cyclin D1 was
expressed in strands of lesional cells, strongly suggesting that there
is an enhanced replicative pool of undifferentiated cells supporting
tumor growth. Remarkably, this pattern of cyclin D1 accumulation
was recapitulated in human SCC (Fig. 6D), suggesting a conserved
Figure 4. Notch signaling deficiency
induces cutaneous SCC formation in mice.
A, representative 8-month-old SM22-Cre+/
DNMAML1+ mouse displaying multiple skin
lesions (I-III ) in addition to diffuse alopecia.
B to E, gross view of lesion I (B ) and H&E
analyses under low power (C ) and high
power of boxed regions (D and E) displaying
surface parakeratin, disorganized
keratinocyte dysplasia with strands of
infiltrating atypical squamous epithelial cells
(D, arrows ), keratin pearls (D and E,
asterisks ), and mitotic figures (E, arrow)
consistent with SCC. F to I, gross view of
lesion II (F ) and H&E analyses under low
power (G ) and high power of boxed regions
(H and I ) displaying similar histologic
features as lesion I, consistent with SCC.
Asterisks, keratin pearl; arrow, mitotic figure.
J and K , gross view of lesion III (J ) and H&E
analysis (K ) showing abundant parakeratin
with underlying suprabasilar epidermal
expansion resembling actinic keratosis.
Spontaneous SCC in Notch Signaling–Deficient Mice
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functional role for cyclin D1 in the pathogenesis of SCC. Taken
together, enhanced levels of nuclear h-catenin and cyclin D1
accumulation in SM22-Cre+/DNMAML1+ epidermis suggests a
molecular model in which loss of CSL-dependent Notch activity
promotes aberrant suprabasilar keratinocyte proliferation facilitat-
ing SCC formation. Furthermore, the presence of nuclear h-catenin
and cyclin D1 expression in SCC may be important for sustained
tumor growth.
Discussion
In this study, we determined that selective inhibition of Notch
signaling in the epidermis results in the spontaneous formation of
cutaneous SCC as well as its precursor lesion, actinic keratosis. To
our knowledge, this is the first report linking inhibition of CSL-
dependent Notch signaling with the de novo development of
SCC. Moreover, in SM22-Cre+/DNMAML1+ mice, accumulation of
nuclear h-catenin and up-regulation of cyclin D1 gene expression
Figure 5. Notch signaling deficiency is
associated with enriched epidermal nuclear
h-catenin and cyclin D1 expression. A to F,
immunohistochemical analyses comparing
pattern of h-catenin expression in backskin
from SM22-Cre/DNMAML1+ (A-C ) and
SM22-Cre+/DNMAML1+ (D-F ) mice.
h-Catenin staining is shown in red and
nuclei in blue (Hoechst ). Arrows, cell
membrane–bound h-catenin; arrowheads,
nuclear h-catenin. Drawn white contour lines
delineate cornified surface layer, which
produces a background fluorescent signal
artifact. G to L, immunohistochemical
analyses showing pattern of cyclin D1
expression in backskin from SM22-Cre/
DNMAML1+ (G-I ) and SM22-Cre+/
DNMAML1+ (J-L ) mice. Cyclin D1 staining is
shown in red and nuclei in blue (Hoechst ).
Arrowheads, underlying basal cyclin D1
expression (G and I ) and enriched
expression in suprabasilar keratinocytes
from SM22-Cre+/DNMAML1+ epidermis
(J and L). Drawn white contour lines
delineate cornified surface layer, which
again produces a background fluorescent
signal artifact.
Figure 6. h-Catenin and cyclin D1 display similar
expression patterns within cutaneous SCCs from
SM22-Cre+/DNMAML1+ mice and humans. A and B,
immunohistochemical analyses showing representative
patterns of h-catenin expression in SCC from a
SM22-Cre+/DNMAML1+ mouse (A ) and spontaneous
human SCC (B). h-Catenin staining is shown in red
and nuclei in blue (Hoechst ) under high power
magnification. Arrows, cell membrane-bound h-catenin;
arrowheads, nuclear h-catenin. Drawn white contour lines
delineate border zones of keratin plugs. C and D,
immunohistochemical analyses showing representative
pattern of cyclin D1 expression in SCC from a SM22-Cre+/
DNMAML1+ mouse (C ) and in spontaneous human SCC
(D ). Cyclin D1 staining is shown in red and nuclei in blue
(Hoechst ) under low-power magnification. Arrowheads,
cells expressing cyclin D1. Drawn white contour lines
delineate border zones of keratin plugs as in (A and B ).
Cancer Research
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were observed, findings recapitulated in biopsies of patients
diagnosed with cutaneous SCC. These observations extend the
proposed function of the Notch1 receptor as a tumor suppressor of
BCC (10) and reveal that pan-inhibition of canonical Notch signal-
ing promotes spontaneous SCC. Taken together, these observations
strongly suggest that Notch signaling may play a critical role in the
pathogenesis of both BCC and SCC, disease processes originating
from epidermal cells that exhibit profoundly different clinical
manifestations (12, 14).
Previous studies revealed that activation of Notch signaling
blocks formation of human cervical, prostate, liver, and lung
malignancies ( for review, see ref. 11). By contrast, activation of
Notch signaling leads to oncogenic transformation in human T-cell
acute lymphoblastic leukemia and murine mammary tumors
(35–37). It has also been recently reported that activation of
Notch signaling promotes formation of human melanoma (38),
a cutaneous malignancy with significant metastatic potential and a
grave prognosis if not diagnosed early in its course (39). These
apparent contradictory functions of Notch signaling show that the
ultimate effect of Notch receptor activation and signaling is
dependent on its precise cellular context. Notch signaling has
been shown to influence cellular differentiation, proliferation, and
survival in both physiologic and oncogenic contexts. Which of
these variables are affected by loss of Notch signaling in SCC
remains to be determined. Ultimately, elucidating the precise
transcriptional targets of Notch in SCC will provide important
insights into the ability of this pathway to protect against both SCC
and precursor lesion development.
Insights into the molecular pathogenesis of cutaneous SCC are
slowly emerging (17, 40, 41). Previous studies have shown that loss
of nuclear factor nB (NF-nB) activity, through enhanced InB
expression, or depletion of SMAD4 in murine skin confers
susceptibility to SCC, in part, through promotion of unbalanced
keratinocyte proliferation (41–46). The demonstration that inhibi-
tion of canonical Notch signaling also promotes de novo SCC
suggests that combinatorial signaling pathways targeting the
keratinocyte underlie the pathogenesis of cutaneous SCC. In this
regard, it is noteworthy that hyperproliferative epidermis was
observed in response to both disrupted NF-nB and Notch signaling,
suggesting that hyperproliferation of keratinocytes may play an
obligatory role in the pathogenesis of cutaneous SCC or in some
way predispose to malignant transformation of keratinocytes.
Moreover, as in humans, actinic keratoses were observed in SM22-
Cre+/DNMAML1+ mice, showing that inhibition of Notch signaling
may underlie the pathogenesis of the premalignant lesion, as well
as cutaneous SCC. As such, at least in this mouse model, Notch
signaling seems to repress the premalignant lesion that gives rise
to the malignant SCC lesion.
The observed accumulation of nuclear h-catenin in epidermal
cells and its detection in SCCs observed in the SM22-Cre+/
DNMAML1+ mutant mice supports previous studies showing
that h-catenin signaling is regulated (i.e., repressed) directly or
indirectly by Notch signaling (47, 48). Consistent with these
findings, the demonstration that signaling-active h-catenin inhi-
bits keratinocyte differentiation (49) and that enhanced levels
of h-catenin are observed in SCC lesions (ref. 30 and references
therein) supports a model wherein h-catenin-mediated Wnt
signaling plays a critical role in malignant transformation of
keratinocytes.
Understanding how inhibition of Notch1 in the skin gives rise
to BCC while pan-inhibition of canonical Notch signaling in the
skin gives rise to de novo development of SCC is a fundamentally
important question that should provide important insights into
the molecular mechanisms that govern the behavior of these two
common skin malignancies. Despite intense investigation in this
area, CSL-dependent Notch target genes have not been clearly
identified in adult epidermis in vivo (8). However, the finding that
expression of the CSL-dependent Notch target genes, HRT1, HRT2 ,
and HRT3 , is down-regulated, and not induced, in vascular smooth
muscle cells harvested from SM22-Cre+/DNMAML1+ mice (which
express DNMAML1 protein) exposed to Jagged1 ligand supports
the conclusion that de novo formation of SCC resulted from
perturbations in CSL-dependent Notch signaling (data not shown).
In this regard, it is noteworthy that in the conditional Notch1-
deficient mice, activated h-catenin, as well as increased levels of
Gli2, a target of activated sonic hedgehog (SHH), was observed (10).
In addition, decreased p21 levels were observed. Thus, it is
tempting to speculate that the magnitude of h-catenin activation
in response to Notch inhibition may differentially lead to BCC
versus SCC. Indeed, the level of h-catenin signaling activity, in part,
has been proposed to account for differences in tumor types
derived from follicular keratinocytes (31, 50). Alternatively,
inhibition of Notch1 function may activate and/or repress only a
subset of the genes regulated directly or indirectly by the canonical
Notch signaling pathway in keratinocytes, suggesting that specific
Notch receptors expressed on the surface of the keratinocyte may
mediate distinct and critical functions in restricting malignant
potential.
To our knowledge, this is the first Notch-deficient murine model
that develops de novo cutaneous SCC. It is noteworthy that this
mouse model recapitulates multiple features of human SCC
including (i) its association with hyperproliferative epidermis, (ii)
association with precursor lesions (actinic keratoses), (iii) sponta-
neous development associated with increasing age, (iv) cellular
histology and pathology, and (v) accumulation of nuclear h-
catenin. Consistent with these findings, a previous study reporting
the phenotype of mice harboring a conditional null mutation of
the CSL gene selectively in the epidermis showed progressive loss
of hair follicles and the generation of dermal keratin cysts (27).
However, in contrast to SM22-Cre+/DNMAML1+ mice, spontaneous
formation of SCC was not described in these mice (27). As inhib-
ition of CSL and expression of DNMAML1 protein should in theory
both inhibit canonical Notch signaling, it remains unclear why
SCC was not observed in these CSL conditional mutant mice. This
difference could be related to differences in specificity of the
promoter driving cell lineage–restricted Cre-mediated recombina-
tion (Nestin-Cre+ versus SM22-Cre+), timing of Cre-mediated
excision, and/or efficiency of Cre excision. Nevertheless, because
they recapitulate multiple aspects of human SCC, SM22-Cre+/
DNMAML1+ mice should serve as a valuable animal model to
elucidate the molecular basis of SCC and to evaluate novel ther-
apeutic strategies.
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